Therapies utilizing VSV as an oncolytic agent have been shown to demonstrate a variety of immune responses, including the induction of tumor-specific CD8+ T cells that are induced following the release of tumor-associated antigens [64]. This evidence concerns the gene CD8A and neoplasm.